The US Department of Justice’s False Claims Act lawsuit against Teva over alleged illegal kickbacks involving Copaxone (glatiramer acetate) is “an overreach, based on a flawed legal theory,” the Israeli firm has argued in filing to have the case dismissed.
DoJ Copaxone Kickback Suit ‘Flawed’ And An ‘Overreach,’ Teva Says
Teva Has Filed Motion To Dismiss FCA Complaint
Teva was accused by the US Department of Justice of violating anti-kickback law in donating money to charities that was later used to cover patient co-pays for Copaxone. In a rebuke aimed at having the suit dismissed, the Israeli manufacturer labelled the DoJ’s suit as “fatally flawed.”
More from Legal & IP
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.
• By
In a precedential decision, the US Court of Appeals for the Federal Circuit has determined the meaning of the language “the patent” as it applies to patent-term extensions for reissued patents, in the context of Aurobindo’s bid to wipe out a reissued patent shielding Merck & Co’s Bridion (sugammadex) injectable.
• By
Novartis’ multi-front legal battle against MSN Laboratories over its Entresto blockbuster in the US has taken yet another twist, with a federal district court in New Jersey finding that a preliminary injunction was warranted against MSN’s product on the basis of infringement of Novartis’ trade dress.
• By
Walmart has launched an attack on a host of industry-leading generics firms over historical price-fixing allegations, with the US retail giant seeking treble damages from a Pennsylvania district court.
More from Generics Bulletin
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
• By
The EMA has accepted for review Henlius’ Perjeta biosimilar, which is to be commercialized by the Chinese company’s global partner Organon in the EU.